<DOC>
	<DOCNO>NCT00696176</DOCNO>
	<brief_summary>The primary goal study evaluate safety transcription factor decoy target Signal Transducer Activator Transcription 3 ( STAT3 ) patient head neck cancer . The rationale target STAT3 use approach decrease STAT3-mediated gene regulation . The study follow scientific objective : 1 . To assess safety single dose intratumoral STAT3 decoy . 2 . To estimate effect STAT3 decoy therapy STAT3 activation level , STAT3-mediated gene expression , apoptosis treat tumor .</brief_summary>
	<brief_title>STAT3 DECOY Head Neck Cancer</brief_title>
	<detailed_description>The decision proceed exploratory IND study conduct phase 0 setting base upon expectation trial involve limit human exposure STAT3 decoy , administer , therapeutic diagnostic intent . Rather , trial design determine intratumoral administration STAT3 decoy human head neck tumor inhibit STAT3 target gene expression . Given cumulative evidence support STAT3 therapeutic target cancer , absence clinical trial date use STAT3 inhibitor , felt would utility proof principal study determine STAT3 decoy inhibits expression STAT3 target gene human head neck cancer . To support propose study design , Grandis lab carry kinetic study xenograft model SCCHN . Preliminary result demonstrate administration STAT3 decoy , mutant control decoy , decrease expression STAT3 target gene ( Bcl-xL and/or Cyclin D1 ) time point range 1 6 hour .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis head neck squamous cell carcinoma ( primary recurrent ) amenable surgical resection . ECOG performance status 0 , 1 , 2 . Adequate organ function Age great equal 18 year Written inform consent . Patients second primary lesion eligible trial . Negative pregnancy test , nonlactating , use effective mean contraception childbearing potential . Subjects fail meet criterion . Subjects pregnant . Subjects ECOG performance status &gt; 2 . Subjects tumor small biopsy prior resection reserve portion resect specimen research purpose . Subjects receive neoadjuvant radiotherapy and/or chemotherapy within four week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>STAT 3 DECOY</keyword>
</DOC>